Intrathecal ELP-02 gene therapy for Charcot-Marie-Tooth Type 4J

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, open-label Phase 1/2 study evaluating safety, tolerability, and potential efficacy of a single lumbar intrathecal dose of the AAV9-based vector ELP-02, which expresses FIG4. The trial will monitor how participants tolerate the treatment and whether it can stabilize or improve motor function and related symptoms in individuals with CMT4J caused by FIG4 gene mutations. Enrollment targets individuals aged 3 to 20 with confirmed bi-allelic FIG4 mutations (one must be I41T) and limited disease severity. Primary sites are at Stanford and the University of Iowa, with Elpida Therapeutics SPC as lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and females between the ages of 3 and 20 years at the time of screening.
* Molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab) due to bi-allelic pathogenic variants (by ACMG criteria) in the FIG4 gene where one of the mutations must be the pathogenic I41T variant, with the second mutation either being another pathogenic or likely pathogenic variant (by ACMG criteria).
* Clinical signs and symptoms consistent with CMT4J disease/motor symptoms
* No more than moderate severity of the disease as measured by a CMTPeds score of \<35 or investigator's discretion
* Written informed consent provided by subject/parent/guardian and willingness to participate and comply with all the study related visits and procedures. Assent provided by children 10 to 17 years old based on their ability to understand the risks and possible benefits, and the activities expected of them.
* Subjects able to reproduce must use a barrier method of contraception for the first 12 months after dosing as well as at least one additional acceptable birth control method if sexually active
* Male subjects must agree not to donate sperm for the remainder of their lifetime after receiving ELP-02
* Female subjects must agree not to donate eggs for the remainder of their lifetime after receiving ELP-02

Exclusion Criteria:

* Prior or ongoing medical condition, medical history, physical findings, cardiovascular/ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
* Clinically significant abnormal laboratory values (hemoglobin \< 6 or \> 20 g/dL; white blood cell \> 20,000 per cmm, platelets count \< 100,000 per cmm; INR \> ULN; GGT, ALT, and AST or total bilirubin \> 2x ULN, creatinine ≥ 1.5 mg/dL) prior to gene replacement therapy.
* History of HbA1C \> 6.0%
* Contraindication or unwillingness to undergo lumbar puncture.
* Presence of a concomitant medical condition that precludes use of anesthetics for sedated procedures.
* History of hypersensitivity to sirolimus, tacrolimus, corticosteroids, gadolinium, iodine or shellfish.
* Concomitant chronic drug treatment that would cause clinically significant interactions with immunosuppressive agents used in the study.
* The presence of significant CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.
* Recent or planned elective surgical procedures that would confound the scientific rigor or interpretation of results of the study.
* Reason to believe that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.
* Have received an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.
* Enrollment and participation in another interventional clinical trial 90 days before first visit.
* Diagnosis of a second neurodegenerative/peripheral neuropathy disease or another genetic syndrome with a progressive course.
* Advanced stage disease defined by the use of chronic invasive ventilatory support (tracheostomy with ventilator dependence) and a non-communicative status.
* Active viral infection (including HIV or serology positive for Hepatitis B or C, or COVID-19).
* Bacterial infection requiring antibiotics within the 6 weeks prior to infusion.
* Positive beta hCG pregnancy test (females of childbearing age will have pregnancy test at Screening and Day-1).

Where it's running

• Stanford University
  Palo Alto, California, United States Recruiting
• University of Iowa
  Iowa City, Iowa, United States Not yet recruiting

Study contacts

• Study coordinator: Rachel Thomas, RN
• Email: studyinfo@elpidatx.com
• Phone: 1-833-335-7432

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tremor in Charcot–Marie–Tooth disease

  Try to characterize tremor in adults with Charcot–Marie–Tooth (CMT) disease using surface electromyography, accelerometers, a clinical exam and questionnaires to see how tremor affects daily life.

  Recruiting University Medical Center Goettingen · Göttingen, Lower Saxony · NCT07570459

• MORC2 gene changes and how they relate to nerve and developmental symptoms

  This project will try to see if specific changes in the MORC2 gene explain why some people develop Charcot–Marie–Tooth nerve problems while others have broader developmental delays, growth impairment, facial differences, and neuropathy.

  Recruiting at 12 sites Hospices Civils de Lyon · Besançon and 11 other locations · NCT07038239

• High-tech rehabilitation program for adults with chronic neuromuscular diseases

  This trial will test whether a high-tech rehab program using robotic systems, virtual reality, and balance platforms works as well as traditional rehab to reduce fatigue and improve function in adults with chronic neuromuscular diseases.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Genova and 6 other locations · NCT06881979

• Observing walking patterns in patients with neuromuscular diseases

  This study is testing how walking patterns change in people with neuromuscular diseases and whether wearable sensors can help track their daily activity and fatigue levels.

  Recruiting IRCCS Eugenio Medea · Bosisio Parini, Lecco and 1 other locations · NCT06666816

• Understanding Pyrimidine and Purine Metabolism Disorders

  This study is trying to learn more about pyrimidine and purine metabolism disorders by comparing affected people with their healthy family members to see what factors might influence their condition.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06092346

• Understanding Charcot-Marie-Tooth Disease through patient data

  This study is collecting information from people with Charcot-Marie-Tooth Disease to better understand their experiences and help improve future treatments.

  Recruiting Hereditary Neuropathy Foundation · New York, New York · NCT05902351

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.